 | • レポートコード：MRC2-11QY12579 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は悪性神経膠腫治療薬のグローバル市場について調査・分析したレポートです。種類別（アルキル化剤、VEGF/VEGFR阻害剤、抗血管新生薬）市場規模、用途別（病院、がん研究機関、診断センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別悪性神経膠腫治療薬の競争状況、市場シェア ・世界の悪性神経膠腫治療薬市場：種類別市場規模 2015年-2020年（アルキル化剤、VEGF/VEGFR阻害剤、抗血管新生薬） ・世界の悪性神経膠腫治療薬市場：種類別市場規模予測 2021年-2026年（アルキル化剤、VEGF/VEGFR阻害剤、抗血管新生薬） ・世界の悪性神経膠腫治療薬市場：用途別市場規模 2015年-2020年（病院、がん研究機関、診断センター、その他） ・世界の悪性神経膠腫治療薬市場：用途別市場規模予測 2021年-2026年（病院、がん研究機関、診断センター、その他） ・北米の悪性神経膠腫治療薬市場分析：米国、カナダ ・ヨーロッパの悪性神経膠腫治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの悪性神経膠腫治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の悪性神経膠腫治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの悪性神経膠腫治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Merck、Eli Lilly、AbbVie、Bristol-Myers Squibb、Genentech、Sun Pharmaceutical、BioMimetix、Cipla、Sigma-Aldrich、Panacea Biotec、Zydus Cadila ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers.
In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and prevalence cases, followed by Europe where the major pharmaceuticals have their blockbuster drugs and include the major funding associations.
Market Analysis and Insights: Global Malignant Glioma Drugs Market
The global Malignant Glioma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Malignant Glioma Drugs Scope and Market Size
Malignant Glioma Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Glioma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Merck
Eli Lilly
AbbVie
Bristol-Myers Squibb
Genentech
Sun Pharmaceutical
BioMimetix
Cipla
Sigma-Aldrich
Panacea Biotec
Zydus Cadila
Market segment by Type, the product can be split into
Alkylating Agents
VEGF/VEGFR Inhibitors
Anti Angiogenic Drugs
Market segment by Application, split into
Hospitals
Cancer Research Organizations
Diagnostic Centers
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Malignant Glioma Drugs Revenue
1.4 Market by Type
1.4.1 Global Malignant Glioma Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Alkylating Agents
1.4.3 VEGF/VEGFR Inhibitors
1.4.4 Anti Angiogenic Drugs
1.5 Market by Application
1.5.1 Global Malignant Glioma Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Organizations
1.5.4 Diagnostic Centers
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Malignant Glioma Drugs Market Perspective (2015-2026)
2.2 Global Malignant Glioma Drugs Growth Trends by Regions
2.2.1 Malignant Glioma Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Malignant Glioma Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Malignant Glioma Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Malignant Glioma Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Malignant Glioma Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Malignant Glioma Drugs Players by Market Size
3.1.1 Global Top Malignant Glioma Drugs Players by Revenue (2015-2020)
3.1.2 Global Malignant Glioma Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Malignant Glioma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Malignant Glioma Drugs Market Concentration Ratio
3.2.1 Global Malignant Glioma Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Malignant Glioma Drugs Revenue in 2019
3.3 Malignant Glioma Drugs Key Players Head office and Area Served
3.4 Key Players Malignant Glioma Drugs Product Solution and Service
3.5 Date of Enter into Malignant Glioma Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Malignant Glioma Drugs Historic Market Size by Type (2015-2020)
4.2 Global Malignant Glioma Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Malignant Glioma Drugs Market Size by Application (2015-2020)
5.2 Global Malignant Glioma Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Malignant Glioma Drugs Market Size (2015-2020)
6.2 Malignant Glioma Drugs Key Players in North America (2019-2020)
6.3 North America Malignant Glioma Drugs Market Size by Type (2015-2020)
6.4 North America Malignant Glioma Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Malignant Glioma Drugs Market Size (2015-2020)
7.2 Malignant Glioma Drugs Key Players in Europe (2019-2020)
7.3 Europe Malignant Glioma Drugs Market Size by Type (2015-2020)
7.4 Europe Malignant Glioma Drugs Market Size by Application (2015-2020)
8 China
8.1 China Malignant Glioma Drugs Market Size (2015-2020)
8.2 Malignant Glioma Drugs Key Players in China (2019-2020)
8.3 China Malignant Glioma Drugs Market Size by Type (2015-2020)
8.4 China Malignant Glioma Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Malignant Glioma Drugs Market Size (2015-2020)
9.2 Malignant Glioma Drugs Key Players in Japan (2019-2020)
9.3 Japan Malignant Glioma Drugs Market Size by Type (2015-2020)
9.4 Japan Malignant Glioma Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Malignant Glioma Drugs Market Size (2015-2020)
10.2 Malignant Glioma Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Malignant Glioma Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Malignant Glioma Drugs Market Size by Application (2015-2020)
11 India
11.1 India Malignant Glioma Drugs Market Size (2015-2020)
11.2 Malignant Glioma Drugs Key Players in India (2019-2020)
11.3 India Malignant Glioma Drugs Market Size by Type (2015-2020)
11.4 India Malignant Glioma Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Malignant Glioma Drugs Market Size (2015-2020)
12.2 Malignant Glioma Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Malignant Glioma Drugs Market Size by Type (2015-2020)
12.4 Central & South America Malignant Glioma Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview
13.1.3 Merck Malignant Glioma Drugs Introduction
13.1.4 Merck Revenue in Malignant Glioma Drugs Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Malignant Glioma Drugs Introduction
13.2.4 Eli Lilly Revenue in Malignant Glioma Drugs Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 AbbVie
13.3.1 AbbVie Company Details
13.3.2 AbbVie Business Overview
13.3.3 AbbVie Malignant Glioma Drugs Introduction
13.3.4 AbbVie Revenue in Malignant Glioma Drugs Business (2015-2020)
13.3.5 AbbVie Recent Development
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Details
13.4.2 Bristol-Myers Squibb Business Overview
13.4.3 Bristol-Myers Squibb Malignant Glioma Drugs Introduction
13.4.4 Bristol-Myers Squibb Revenue in Malignant Glioma Drugs Business (2015-2020)
13.4.5 Bristol-Myers Squibb Recent Development
13.5 Genentech
13.5.1 Genentech Company Details
13.5.2 Genentech Business Overview
13.5.3 Genentech Malignant Glioma Drugs Introduction
13.5.4 Genentech Revenue in Malignant Glioma Drugs Business (2015-2020)
13.5.5 Genentech Recent Development
13.6 Sun Pharmaceutical
13.6.1 Sun Pharmaceutical Company Details
13.6.2 Sun Pharmaceutical Business Overview
13.6.3 Sun Pharmaceutical Malignant Glioma Drugs Introduction
13.6.4 Sun Pharmaceutical Revenue in Malignant Glioma Drugs Business (2015-2020)
13.6.5 Sun Pharmaceutical Recent Development
13.7 BioMimetix
13.7.1 BioMimetix Company Details
13.7.2 BioMimetix Business Overview
13.7.3 BioMimetix Malignant Glioma Drugs Introduction
13.7.4 BioMimetix Revenue in Malignant Glioma Drugs Business (2015-2020)
13.7.5 BioMimetix Recent Development
13.8 Cipla
13.8.1 Cipla Company Details
13.8.2 Cipla Business Overview
13.8.3 Cipla Malignant Glioma Drugs Introduction
13.8.4 Cipla Revenue in Malignant Glioma Drugs Business (2015-2020)
13.8.5 Cipla Recent Development
13.9 Sigma-Aldrich
13.9.1 Sigma-Aldrich Company Details
13.9.2 Sigma-Aldrich Business Overview
13.9.3 Sigma-Aldrich Malignant Glioma Drugs Introduction
13.9.4 Sigma-Aldrich Revenue in Malignant Glioma Drugs Business (2015-2020)
13.9.5 Sigma-Aldrich Recent Development
13.10 Panacea Biotec
13.10.1 Panacea Biotec Company Details
13.10.2 Panacea Biotec Business Overview
13.10.3 Panacea Biotec Malignant Glioma Drugs Introduction
13.10.4 Panacea Biotec Revenue in Malignant Glioma Drugs Business (2015-2020)
13.10.5 Panacea Biotec Recent Development
13.11 Zydus Cadila
10.11.1 Zydus Cadila Company Details
10.11.2 Zydus Cadila Business Overview
10.11.3 Zydus Cadila Malignant Glioma Drugs Introduction
10.11.4 Zydus Cadila Revenue in Malignant Glioma Drugs Business (2015-2020)
10.11.5 Zydus Cadila Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Malignant Glioma Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Malignant Glioma Drugs Revenue
Table 3. Ranking of Global Top Malignant Glioma Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Malignant Glioma Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Alkylating Agents
Table 6. Key Players of VEGF/VEGFR Inhibitors
Table 7. Key Players of Anti Angiogenic Drugs
Table 8. Global Malignant Glioma Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Malignant Glioma Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Malignant Glioma Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Malignant Glioma Drugs Market Share by Regions (2015-2020)
Table 12. Global Malignant Glioma Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Malignant Glioma Drugs Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Malignant Glioma Drugs Market Growth Strategy
Table 18. Main Points Interviewed from Key Malignant Glioma Drugs Players
Table 19. Global Malignant Glioma Drugs Revenue by Players (2015-2020) (Million US$)
Table 20. Global Malignant Glioma Drugs Market Share by Players (2015-2020)
Table 21. Global Top Malignant Glioma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Drugs as of 2019)
Table 22. Global Malignant Glioma Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Malignant Glioma Drugs Product Solution and Service
Table 25. Date of Enter into Malignant Glioma Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Malignant Glioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 28. Global Malignant Glioma Drugs Market Size Share by Type (2015-2020)
Table 29. Global Malignant Glioma Drugs Revenue Market Share by Type (2021-2026)
Table 30. Global Malignant Glioma Drugs Market Size Share by Application (2015-2020)
Table 31. Global Malignant Glioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 32. Global Malignant Glioma Drugs Market Size Share by Application (2021-2026)
Table 33. North America Key Players Malignant Glioma Drugs Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Malignant Glioma Drugs Market Share (2019-2020)
Table 35. North America Malignant Glioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 36. North America Malignant Glioma Drugs Market Share by Type (2015-2020)
Table 37. North America Malignant Glioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 38. North America Malignant Glioma Drugs Market Share by Application (2015-2020)
Table 39. Europe Key Players Malignant Glioma Drugs Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Malignant Glioma Drugs Market Share (2019-2020)
Table 41. Europe Malignant Glioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Malignant Glioma Drugs Market Share by Type (2015-2020)
Table 43. Europe Malignant Glioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Malignant Glioma Drugs Market Share by Application (2015-2020)
Table 45. China Key Players Malignant Glioma Drugs Revenue (2019-2020) (Million US$)
Table 46. China Key Players Malignant Glioma Drugs Market Share (2019-2020)
Table 47. China Malignant Glioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 48. China Malignant Glioma Drugs Market Share by Type (2015-2020)
Table 49. China Malignant Glioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 50. China Malignant Glioma Drugs Market Share by Application (2015-2020)
Table 51. Japan Key Players Malignant Glioma Drugs Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Malignant Glioma Drugs Market Share (2019-2020)
Table 53. Japan Malignant Glioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Malignant Glioma Drugs Market Share by Type (2015-2020)
Table 55. Japan Malignant Glioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Malignant Glioma Drugs Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Malignant Glioma Drugs Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Malignant Glioma Drugs Market Share (2019-2020)
Table 59. Southeast Asia Malignant Glioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Malignant Glioma Drugs Market Share by Type (2015-2020)
Table 61. Southeast Asia Malignant Glioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Malignant Glioma Drugs Market Share by Application (2015-2020)
Table 63. India Key Players Malignant Glioma Drugs Revenue (2019-2020) (Million US$)
Table 64. India Key Players Malignant Glioma Drugs Market Share (2019-2020)
Table 65. India Malignant Glioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 66. India Malignant Glioma Drugs Market Share by Type (2015-2020)
Table 67. India Malignant Glioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 68. India Malignant Glioma Drugs Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Malignant Glioma Drugs Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Malignant Glioma Drugs Market Share (2019-2020)
Table 71. Central & South America Malignant Glioma Drugs Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Malignant Glioma Drugs Market Share by Type (2015-2020)
Table 73. Central & South America Malignant Glioma Drugs Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Malignant Glioma Drugs Market Share by Application (2015-2020)
Table 75. Merck Company Details
Table 76. Merck Business Overview
Table 77. Merck Product
Table 78. Merck Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 79. Merck Recent Development
Table 80. Eli Lilly Company Details
Table 81. Eli Lilly Business Overview
Table 82. Eli Lilly Product
Table 83. Eli Lilly Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 84. Eli Lilly Recent Development
Table 85. AbbVie Company Details
Table 86. AbbVie Business Overview
Table 87. AbbVie Product
Table 88. AbbVie Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 89. AbbVie Recent Development
Table 90. Bristol-Myers Squibb Company Details
Table 91. Bristol-Myers Squibb Business Overview
Table 92. Bristol-Myers Squibb Product
Table 93. Bristol-Myers Squibb Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 94. Bristol-Myers Squibb Recent Development
Table 95. Genentech Company Details
Table 96. Genentech Business Overview
Table 97. Genentech Product
Table 98. Genentech Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 99. Genentech Recent Development
Table 100. Sun Pharmaceutical Company Details
Table 101. Sun Pharmaceutical Business Overview
Table 102. Sun Pharmaceutical Product
Table 103. Sun Pharmaceutical Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 104. Sun Pharmaceutical Recent Development
Table 105. BioMimetix Company Details
Table 106. BioMimetix Business Overview
Table 107. BioMimetix Product
Table 108. BioMimetix Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 109. BioMimetix Recent Development
Table 110. Cipla Business Overview
Table 111. Cipla Product
Table 112. Cipla Company Details
Table 113. Cipla Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 114. Cipla Recent Development
Table 115. Sigma-Aldrich Company Details
Table 116. Sigma-Aldrich Business Overview
Table 117. Sigma-Aldrich Product
Table 118. Sigma-Aldrich Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 119. Sigma-Aldrich Recent Development
Table 120. Panacea Biotec Company Details
Table 121. Panacea Biotec Business Overview
Table 122. Panacea Biotec Product
Table 123. Panacea Biotec Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 124. Panacea Biotec Recent Development
Table 125. Zydus Cadila Company Details
Table 126. Zydus Cadila Business Overview
Table 127. Zydus Cadila Product
Table 128. Zydus Cadila Revenue in Malignant Glioma Drugs Business (2015-2020) (Million US$)
Table 129. Zydus Cadila Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Glioma Drugs Market Share by Type: 2020 VS 2026
Figure 2. Alkylating Agents Features
Figure 3. VEGF/VEGFR Inhibitors Features
Figure 4. Anti Angiogenic Drugs Features
Figure 5. Global Malignant Glioma Drugs Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Cancer Research Organizations Case Studies
Figure 8. Diagnostic Centers Case Studies
Figure 9. Other Case Studies
Figure 10. Malignant Glioma Drugs Report Years Considered
Figure 11. Global Malignant Glioma Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Malignant Glioma Drugs Market Share by Regions: 2020 VS 2026
Figure 13. Global Malignant Glioma Drugs Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Malignant Glioma Drugs Market Share by Players in 2019
Figure 16. Global Top Malignant Glioma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Drugs as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Malignant Glioma Drugs Revenue in 2019
Figure 18. North America Malignant Glioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Malignant Glioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Malignant Glioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Malignant Glioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Malignant Glioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Malignant Glioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Malignant Glioma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
悪性神経膠腫の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…- 悪性神経膠腫治療の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 成人用悪性神経膠腫治療薬の世界市場（～2026年） Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pip…
- 悪性中皮腫治療薬の世界市場（～2026年） Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the foreca…
- 悪性リンパ腫の世界市場（～2026年） Cancers that start anywhere in the body’s lymphatic system are called lymphomas. If they have the ability to spread, they are called malignant. The lymphatic system runs throughout our bodies and is composed of lymphoid tissue, vessels, and fluid. Lymphoid tissue contains lymph nodes, which are part…